Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Glaxo Wellcome Imitrex

Executive Summary

Sumatriptan labeling revised on Feb. 13 to include clinical data showing initial 50 mg and 100 mg doses to be more effective for migraine treatment than the 25 mg dose. Previous labeling recommended starting dose of 25 mg. Imitrex tablets are available in 25 mg and 50 mg tablets i the u.S.; 100 mg tabs are available internationally...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS031709

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel